The origin of migraine pain has not yet been clarified, but accumulating data point to neuropeptides present in the perivascular space of cranial vessels as important mediators of nociceptive input during migraine attacks. Pituitary adenylate cyclase-activating polypeptide (PACAP) is present in sensory trigeminal neurons and may modulate nociception at different levels of the nervous system. Human experimental studies have shown that PACAP-38 infusion induces marked dilatation of extracerebral vessels and delayed migraine-like attacks in migraine patients. PACAP selectively activates the PAC 1 receptor, which suggests a possible signaling pathway implicated in migraine pain. This review summarizes the current evidence supporting the involvement of PACAP in migraine pathophysiology and the PAC 1 receptor as a possible novel target for migraine treatment.
INTRODUCTION
Migraine patients experience intense head pain during attacks, which results in disability and high socioeconomic costs. 1 Thus, clinical research to discover new specific drug targets for migraine is highly needed. 2 The origin of pain during migraine attacks is still not fully elucidated. Activation of peripheral trigeminal nociceptors in the perivascular space of cranial arteries probably generates input that leads to the experience of migraine pain. 3 In support of this view, it has been shown that signaling molecules, such as nitric oxide (NO) and calcitonin gene-related peptide (CGRP), found in nerve fibers surrounding cranial arteries, 4 -7 induce migraine-like attacks indistinguishable from spontaneous migraine attacks. 8, 9 Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide present in the perivascular space of cranial arteries. Recent studies point to the involvement of PACAP in migraine pain. 10 Here we review the evidence on how PACAP might be implicated in specific receptor activation during migraine attacks and discuss how the PAC 1 receptor could be a novel target for migraine treatment.
PACAP STRUCTURE, DISTRIBUTION, AND RECEPTORS
PACAP was originally isolated in the late 1980s from an ovine hypothalamus extract on the basis of its ability to stimulate cAMP formation in rat pituitary cells.
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PACAP belongs to the vasoactive intestinal polypeptide (VIP)-secretin-growth hormone-releasing hormoneglucagon superfamily 12 and is found as a 38-amino-acid peptide (PACAP-38) and a truncated 27-amino-acid peptide (PACAP-27). PACAP-38 is the predominant peptide and represents more than 90% of the total PACAP content in most tissues, including the CNS. [13] [14] [15] [16] PACAP has been identified in human sensory 17 and parasympathetic 4 ganglia, as well as in second-order neurons of the trigeminal nucleus caudalis (TNC). 18 The N-terminal 28 amino acids of PACAP-38 share 68% homology with VIP, 19 and the two related peptides are colocalized in rat parasympathetic ganglia. 5, 20 The action of PACAP is mediated through three Gprotein coupled receptors: VPAC 1 and VPAC 2 , which have an equally high affinity for PACAP and VIP, and PAC 1 , which has a 1000-fold higher affinity for PACAP than for VIP. 21 Activation of all three receptors increases cAMP; phospholipase C (PLC) and intracellular calcium have also been reported as effector pathways 22, 23 (FIG. 1) . The messenger RNAs for all PACAP receptors have been identified in human cerebral arteries 24 and in sen-sory, parasympathetic, and sympathetic ganglia with perivascular nerve fiber projections. 24 In this review we will describe the possible role of PACAP in nociceptive processing in the peripheral and central nervous system relevant for migraine pain.
The peripheral actions of PACAP
Stimulation of the superior sagittal sinus causes a 2.6-fold increase in PACAP plasma concentrations in the external jugular vein in cats. 25 Whether this is caused by PACAP released from trigeminal sensory or parasympathetic perivascular fibers is unknown. Human experimental studies suggest that parasympathetic activation is pronociceptive, in that migraine pain is reduced after anesthetic blocking of the parasympathetic sphenopalatine ganglion. 26, 27 Because parasympathetic and trigeminal fibers are closely related in the perivascular space, 28 it is possible that PACAP released from either system could lead to modulation of sensory input in trigeminal neurons.
Dilatation of cranial vessels might contribute to pain during migraine attacks. 29, 30 PACAP-38 dilates both animal [31] [32] [33] and human 34 cerebral arteries; however, only VPAC 1 receptor antagonists inhibit PACAP-38-induced dilation in the rat middle cerebral artery (MCA) 35 and middle meningeal artery (MMA). 33 In the human coronary artery, PACAP-induced dilatation is not changed by PAC 1 receptor antagonism. 36 These data indicate that activation of the PAC 1 receptor does not contribute to extracranial or intracranial vasodilatation.
During recent years, mast cell degranulation has been suggested to be involved in migraine pathophysiology. 37, 38 The evidence is based primarily on studies
showing that plasma histamine levels are elevated during migraine attacks in a subpopulation of migraine patients, 39 and that histamine induces migraine-like attacks following intravenous infusion. 40 Furthermore, mast cell degranulation causes activation of meningeal nociceptors in the rat dura mater. 41 44 VIP seems to be the more potent than PACAP-38 in degranulating mast cells in vitro. 44 Furthermore, VIP releases a relatively small proportion (10%) of histamine from human dural mast cells, compared with CGRP (10% vs 32%). 45 Thus, it seems unlikely (although it remains to be investigated) that PACAP can induce sufficient mast cell degranulation in the perivascular space of cranial arteries to result in nociceptive input.
Stimulation of both VPAC 1-2 and PAC 1 receptors elevates cAMP, 46 but in cultured neural cells PACAP-38 stimulates adenylate cyclase activity at least 1000 times more than VIP does. 11 Thus, it is possible that PACAP via the PAC 1 receptor could elevate cAMP in peripheral trigeminal nociceptors, resulting in nociception. In fact, animal models in both rat 47 and guinea pig 48 have shown trigeminal neurons to be sensitized through elevation of cAMP. Recently, Akerman and Goadsby 49 also showed that VPAC 1 
The central actions of PACAP
PACAP immunoreactivity is present in the human TNC, 18 but is also found in cell bodies of the brain stem locus coeruleus, 50 which projects to the TNC 51 and is reported to be activated during spontaneous migraine attacks. 52 Animal experimental models have proposed that PACAP might have a role in central pain transmission. 53 Capsaicin elevates PACAP in rat cerebrospinal fluid in vivo, 54 suggesting that PACAP may be released from activated C-fibers in the spinal cord. In PACAP gene knockout mice (Adcyap1 Ϫ/Ϫ ), inflammatory pain disappears 55 and PACAP promotes the functional coupling of neuronal NO-synthase to NMDA receptors. This leads to NO production in superficial layers of the dorsal horn in the spinal cord 55 and late-onset, transcriptionaland activity-dependent central sensitization. 56 PAC 1 receptor knockout mice have a decreased response in nociceptive behavior after a formalin test, 57 which is a model of inflammatory nociception. PAC 1 receptor antagonism also effectively attenuated nociception in inflammatory models of pain in rats 58 and mice 59 after intrathecal administration. These data suggest that activation of the PAC 1 receptor could lead to modulation of nociceptive input in the second-order neurons.
HUMAN PACAP MODEL OF MIGRAINE
The headache eliciting and vasodilatory effect in cranial arteries after infusion of PACAP-38 was examined in 12 healthy volunteers and 12 patients with migraine without aura in a randomized double-blind crossover study.
10 PACAP-38 infusion caused headache in all 12 healthy subjects and in 11 of the 12 migraine patients. The headache peaked 4 -5 hours after the end of infusion (FIG. 2) . The most important finding of the study was that 58% of the migraine patients experienced migrainelike attacks after PACAP-38 infusion; most attacks occurred several hours after the end of infusion. PACAP-38 also induced pronounced dilatation of intra-and extracranial arteries, with maximum at 20 minutes after the start of infusion, which remained sustained throughout the 90-minute recording period (FIG. 3) . VIP, given in exactly the same quantity as PACAP-38 (200 pmol/kg), has been studied in similar studies. 60, 61 These studies showed that the systemic administration of VIP induces only a very mild and short-lasting immediate headache in both healthy subjects 60 and migraineurs. 61 Despite marked immediate vasodilatation, no migraine sufferer reported delayed migraine-like attacks after VIP. Given that VIP infusion does not cause migraine, the shared VPAC 1 and VPAC 2 receptors seem unlikely to be involved in PACAP-38-induced migraine. Thus, migraine induction by PACAP-38 might be caused by selective activation of the PAC 1 receptor.
A recent study attempted to explore pronociceptive properties of PACAP-38 and VIP in humans, using a skin model of acute pain. 62 Pain intensities after VIP and PACAP-38 were mild and limited to a short time, approximately 100 seconds after injection. VIP caused more neurogenic inflammation and mast cell degranulation than did PACAP-38, as reflected in changes in blood skin flow and wheal. Thus, flow and wheal are mediated via the VPAC receptors.
HOW MIGHT PACAP-38 INDUCE MIGRAINE?
At present, there is no firm evidence implicating the PAC 1 receptor in migraine pathophysiology, and no PAC 1 receptor antagonist is available for human use to test this hypothesis. Nonetheless, the ability of PACAP-38 to induce migraine, in contrast to VIP, strongly points to PAC 1 receptor activation as a possible mediator of migraine. Experimental data noted in this review suggest that vasodilatation, 10, 33, 35, 36 mast cell degranulation, 44, 62 and neurogenic inflammation 62 are induced by the VPAC receptors and therefore do not seem important in PACAP-38-induced migraine. Instead, PACAP-38 might modulate the PAC 1 receptors at the second-order trigeminal neurons. After intravenous PACAP-38 administration, however, only 0.053% passes the blood-brain barrier (BBB) after 5 minutes via a saturable mechanism in mice. 63 This suggests that activation of PAC 1 receptors within the BBB is unlikely to mediate PACAP-38-induced migraine.
The most likely explanation for migraine development after administration of PACAP-38 seems to be modulation of dural or extracranial trigeminal nociceptors outside of the BBB. Thus, intracellular cAMP increase in dural nociceptors following PAC 1 activation could be a necessary link in the cascade of events that leads to migraine development. Indeed, the headache-inducing effect of cilostazol, which is known to increase intracellular cAMP, has been tested; 92% of the healthy subjects developed headache, including 18% who had migrainelike features, such as pulsating pain quality and aggravation by physical activity. 64 PACAP-38 and CGRP share the cAMP intracellular signaling pathway, and CGRP also does not pass the BBB freely. 65 Intravenous infusion of CGRP induces migraine-like attacks occurring several hours after the end of the infusion, just as PACAP-38 induced migraine-like attacks, and the CGRP receptor antagonist telcagepant is effective for the acute treatment of migraine. 66 Even though PACAP-38 most likely induces migraine through peripheral modulation, it is possible that a PAC 1 receptor antagonist permeable to the BBB would have a synergetic dual effect at both first-order and second-order trigeminal neurons. A PAC 1 receptor antagonist is likely to be devoid of vascular side effects, which would be beneficial to migraine patients with ischemic vascular comorbidity. Future studies should elucidate the possible pronociceptive effects of the PAC 1 receptor. The development of a PAC 1 receptor antagonist that can be tested in human clinical research would be extremely beneficial for our understanding of migraine mechanisms and possibilities for new treatments.
